Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-110 in Neovascular Age-Related Macular Degeneration
NCT06550011Phase 2Active, not recruiting
- Sponsor
- Avirmax Biopharma
- Start
- Aug 2024
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of ABI-110 in neovascular age-related macular degeneration (NVAMD), polypoidal choroidal vasculopathy (PCV), sponsored by Avirmax Biopharma. Started Aug 2024; status: active, not recruiting.
02
Drugs
ABI-110
03
Conditions
neovascular age-related macular degeneration (NVAMD)polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT06550011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06550011.